This article is a correction to:
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
Daniel A. Ladin1
Eman Soliman
Rukiyah Van Dross- 1Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC, United States
- 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
- 3Center for Health Disparities, East Carolina University, Greenville, NC, United States
A Corrigendum on
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
by Ladin D. A., Soliman E., Griffin L. and Van Dross R. (2016). Front. Pharmacol. 7:361. doi: 10.3389/fphar.2016.00361
In the original article, the Reference for “Blazquez, C. et al. (2006)” was incorrectly written as “Naeem et al. (2006).” The correct and full citation is “Blázquez, C., Carracedo, A., Barrado, L., Real, P. J., Fernández-Luna, J. L., Velasco, G., Malumbres, M., Guzmán, M. (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635. 10.1096/fj.06-6638fje.”
In the original article, the Reference for “Velasco, G., (2016)” was incorrectly written as “Fujimura et al. (1989).” The correct and full citation is “Velasco, G., Hernandez-Tiedra, S., Davila, D., and Lorente, M. (2016). The use of cannabinoids as anticancer agents. Prog. Neuropsychopharmacol. Biol. Psychiarty. 64, 259-266. 10.1016/j.pnpbp 2015.05.010.”
In the original article, the Reference for “Salazar (2009)” was incorrectly written as “Jenkins, M.A., et al. (2006).” The correct and full citation is “Salazar, M., Carracedo, A., Salanueva, I. J., Hernandez-Tiedra, S., Lorente, M., Egia, A., Vazquez, P., Blazquez, C., Torres, S., Garcia, S., Nowak, J., Fimai, G. M., Piacentini, M., Cecconi, F., Pandolfi, P. P., Gonzalez-Feria, L., Iovanna, J. L., Guzman, M., Boya, P., and Velasco, G. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119, 1359-1372. 10.1172/JCI37948.”
In the original article, the Reference for “McKallip (2005)” was incorrectly written as “Martin-Banderas et al. (2015).” The correct and full citation is “McKallip, R. J., Nagarkatti, M., and Nagarkatti, P. S. (2005). Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol 174, 3281-3289. 10.4049/jimmunol.174.6.3281.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: cannabinoids, cancer, in vivo, clinical studies, clinical trials, therapeutics, cancer models, endocannabinoids
Citation: Ladin DA, Soliman E, Griffin L and Van Dross R (2021) Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. Front. Pharmacol. 12:732903. doi: 10.3389/fphar.2021.732903
Received: 29 June 2021; Accepted: 30 June 2021;
Published: 16 July 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Ladin, Soliman, Griffin and Van Dross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rukiyah Van Dross, vandrossr@ecu.edu